<DOC>
	<DOCNO>NCT00004904</DOCNO>
	<brief_summary>RATIONALE : Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill tumor cell . PURPOSE : Phase I trial study effectiveness treat donor stem cell transplantation treat patient hematologic cancer .</brief_summary>
	<brief_title>Stem Cell Transplantation Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine megadose CD34 cell intense immunosuppression administer partially match relate donor ( PMRD ) hematopoietic stem cell ( HSC ) transplantation result engraftment patient high risk hematologic malignancy . II . Determine incidence severity acute grade ( I-IV ) chronic ( limited extensive ) graft versus host disease patient rigorous T-cell depletion PMRD HSC transplantation . OUTLINE : Harvest : Bone marrow peripheral blood stem cell ( PBSC ) harvest related 1 , 2 , 3 HLA antigen mismatch donor . PBSC select CD34+ cell T-cells deplete . Conditioning : Patients undergo total body irradiation twice daily day -10 -7 day -6 . Patients receive cladribine IV continuously day -10 -6 ; etoposide IV 2 hour day -5 ; cyclophosphamide IV 2 hour , antithymocyte globulin ( ATG ) IV 10-12 hour , methylprednisolone IV 1 hour day -4 -2 . Transplantation : T-cell deplete PBSC bone marrow infuse day 0 . Patients receive G-CSF SQ daily begin day 0 continue blood count recover . Graft versus host disease prophylaxis : Patients receive tacrolimus IV every 12 hour begin day -2 continue orally 4 time day 6-12 month discretion protocol investigator . Patients receive ATG IV 10-12 hour methylprednisolone IV 1 hour day 5-15 follow taper methylprednisolone . Patients follow every week day 100 6 12 month . PROJECTED ACCRUAL : A total 12-20 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove hematologic malignancy relapse allogeneic bone marrow transplantation ( BMT ) autologous BMT HLA match sibling donor available OR Histologically proven acute myeloid leukemia ( AML ) without available HLA match sibling donor one following : Failure induction , define inability obtain remission 2 course induction failure treatment Second great remission OR Histologically proven acute lymphocytic leukemia ( ALL ) adult age 15 without available HLA match sibling donor one following : Philadelphia chromosome positivity cytogenetics PCR Relapse second great remission Two prognostic feature ( age 30 , WBC presentation 35,000/mm3 , time complete response 4 week , ( 4:11 ) , Bcell ALL ) OR Histologically proven chronic myelogenous leukemia In chronic phase without A , B , DR unrelated match donor OR In accelerated phase , define new cytogenetic abnormality difficulty maintain normal WBC due dose limit cytopenia ( thrombocytopenias anemia ) hydroxyurea interferon OR In blast transformation OR Histologically proven aplastic anemia without available HLA match sibling donor failure immunosuppressive therapy regimen use either cyclosporine , antithymocyte globulin , OR Histologically proven lymphoma without available HLA match donor failure least 2 different chemotherapy regimen OR Histologically proven cutaneous Tcell lymphoma without available HLA match donor failure interferon PUVA ( psoralen ultraviolet A radiation ) OR Histologically proven myelodysplastic syndrome without available HLA match sibling donor one following : 5 % great blast marrow Multiple cytogenetic abnormality History infection neutropenia 1 , 2 , 3 antigen mismatch related donor available PATIENT CHARACTERISTICS : Age : Physiologic age 45 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 2.0 mg/dL SGOT SGPT great 2 time upper limit normal Renal : Creatinine great 2.0 mg/dL Cardiovascular : No myocardial infarction within past 6 month No coronary artery disease require medical therapy Resting LVEF least 40 % Pulmonary : FEV1/FVC least 60 % predict DLCO least 60 % predict Other : HIV negative No prior malignancy except basal cell squamous cell skin cancer Other malignancy patient cured local surgical therapy , head neck cancer stage I breast cancer , consider individual basis Not pregnant Negative pregnancy test Fertile patient must use effective contraception No psychiatric illness mental deficiency would preclude compliance informed consent PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>